ClinicalTrials.gg
CompletedNCT03430817Updated May 24, 2024

Citicholine-Amantadine Trial in Traumatic Brain Injury

A Phase 4 interventional study of Citicholine and Amantadine in Intensive Care Unit, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Study summary

This randomized study aims at comparing between the effects of amantadine, citcholine and its combinations on arousal and behavioral consequences in early phase of moderate Traumatic Brain injury (TBI).

Read the detailed description

As both agents amantadine and citcholine showed considerable effects on neuro-recovery from TBI, The investigators hypothesized that combination therapy of both drugs will have significant effect as it simultaneously will target multiple mechanisms of injury. So, this randomized study aims at comparing between the effects of amantadine, citcholine and their combinations on arousal and behavioral consequences in early phase of moderate TBI

02

Conditions studied

  • Intensive Care Unit
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sustained moderate non-penetrating TBI with GCS of 9-12

Exclusion criteria

Exclusion Criteria:

  • Patients with mild (GCS > 12) or severe TBI (GCS \< 9)
  • Patients suffering from any central nervous system disability prior to the traumatic brain injury
  • Major medical problems as; major cardiovascular disease or heart failure, renal insufficiency (, less than 60 ml per minute), liver impairment,
  • Pregnancy,
  • More than one seizure in the previous month,
  • Prior treatment with amantadine,
  • Allergy to the study drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Group C

    Citicholine Drug

    Drug: Citicholine

  • Experimental
    Group A

    Amantadine Drug

    Drug: Amantadine

  • Experimental
    Group D

    Both Citocholine and Amantadine

    Drug: Citicholine · Drug: Amantadine

Interventions

  • DrugCytidine Diphosphate CholineStudies of Cytidine Diphosphate CholineCytidine Diphosphate Choline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.

  • Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.

06

What researchers measure

Primary outcomes

  1. Galsgow coma scale

    Neurological scale which aims to give a reliable and objective way of recording the conscious state of a person for initial as well as subsequent assessment. A patient is assessed against the criteria of the scale, and the resulting points give a patient score between 3 (indicating deep unconsciousness) and 15 (full conscious).

    Time frame: 30 days

Secondary outcomes

  1. disability rating scale (DRS)

    The Disability Rating Scale (DRS) was developed and tested with older juvenile and adult individuals with moderate and severe traumatic brain injury (TBI). The maximum score a patient can obtain on the DRS is 29 (extreme vegetative state). A person without disability would score zero. The DRS rating must be reliable, i.e., obtained while the individual is not under the influence of anesthesia, other mind-altering drugs, recent seizure, or recovering from surgical anesthesia.

    Time frame: 30 days

  2. Mini Mental scale (MMS)

    The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.

    Time frame: 30 days

07

Study locations

1 site
  • Ain Shams University hospitals
    Cairo, 11591, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2024, 75 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Feb 13, 2018
StartActual
Dec 7, 2017
Primary completionActual
Mar 24, 2024
CompletionActual
Apr 20, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03430817
Responsible party
Dina Salah Eldin Mahmoud Badre (Assistant Professor, Ain Shams University) — Principal investigator
First posted
Feb 13, 2018
Start date
Dec 7, 2017
Primary completion
Mar 24, 2024
Completion
Apr 20, 2024
Last update
May 24, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cytidine Diphosphate Choline · Amantadine

Start the discussion